We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sysmex and QIAGEN Expand Collaboration in Genetic Testing

By LabMedica International staff writers
Posted on 07 Aug 2024
Print article
Image: Sysmex has expanded its strategic alliance agreement with QIAGEN in the field of genetic testing (Photo courtesy of QIAGEN)
Image: Sysmex has expanded its strategic alliance agreement with QIAGEN in the field of genetic testing (Photo courtesy of QIAGEN)

Sysmex Corporation (Kobe, Japan) has expanded its strategic alliance agreement with QIAGEN N.V. (Venlo, The Netherlands) to deepen their cooperation in genetic testing, encompassing areas such as research and development, manufacturing, clinical development, and sales-marketing.

Sysmex has been a significant player in the in vitro diagnostics arena for over five decades, continually advancing its genetic testing capabilities. A key aspect of this advancement is the deployment of liquid biopsy technologies in product development to deliver personalized medicine solutions to both patients and healthcare professionals. With a robust global sales and service network backed by premier laboratories in Japan and the USA, Sysmex is dedicated to furthering the innovation of diagnostic technologies and high-value testing. Meanwhile, QIAGEN stands as a leader in precision medicine and a primary partner for pharmaceutical and biotech companies, developing companion diagnostics that identify genetic variances to inform clinical treatment decisions. QIAGEN’s technological suite ranges from polymerase chain reaction (PCR), multiplex PCR, digital PCR (dPCR), to next-generation sequencing (NGS), offering tailored solutions to over 30 global pharmaceutical partners through master collaboration agreements.

Since their initial alliance in 2013 and their decision to forge a strategic partnership for companion diagnostics in 2021, Sysmex and QIAGEN have seen considerable collaborative success. With the recent expansion of this partnership, the companies aim to leverage their combined expertise in genetic testing to produce high-value offerings for their global clientele. Under the new terms, Sysmex will integrate QIAGEN’s assays into the clinical trials it conducts for pharmaceutical companies and research institutions across its global network of laboratories, enhancing QIAGEN's global service capabilities.

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Sekisui Diagnostics UK Ltd.